Affiliations 

  • 1 School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
  • 2 Department of Pathology, Hospital Teluk Intan, Teluk Intan, Malaysia
  • 3 Department of Laboratory Medicine, National University Hospital, Singapore
  • 4 Pathology Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia
  • 5 Dorevitch Pathology, Heidelberg, Victoria, Australia
  • 6 Department of Pathology, Northern Health, Epping, Victoria, Australia kayweng.choy@nh.org.au
J Clin Pathol, 2023 Nov;76(11):727-733.
PMID: 37604683 DOI: 10.1136/jcp-2023-208774

Abstract

Monoclonal gammopathy is a spectrum of disorders characterised by clonal proliferation of plasma cells or lymphocytes, which produce abnormal immunoglobulin or its components (monoclonal proteins). Monoclonal gammopathies are often categorised as low-tumour-burden diseases (eg, amyloid light chain (AL) amyloidosis), premalignant disorders (such as monoclonal gammopathy of undetermined significance and smouldering multiple myeloma), and malignancies (eg, multiple myeloma and Waldenström's macroglobulinaemia). Such diversity of concentration and structure makes monoclonal protein a challenging clonal marker. This article provides an overview on initial laboratory testing of monoclonal gammopathy to guide clinicians and laboratory professionals in the selection and interpretation of appropriate investigations.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.